EGFR and non-small cell lung carcinoma: For instance, icotinib, an EGFR-tyrosine kinase inhibitor (TKI), is used to treat non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation (Zhong et al., 2017).